RVMD vs. INSM, BNTX, TEVA, GMAB, SMMT, RDY, ASND, VTRS, ROIV, and QGEN
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.
Revolution Medicines has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -259.82%. Revolution Medicines' return on equity of -41.78% beat Insmed's return on equity.
In the previous week, Insmed had 15 more articles in the media than Revolution Medicines. MarketBeat recorded 21 mentions for Insmed and 6 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.79 beat Insmed's score of 0.66 indicating that Revolution Medicines is being referred to more favorably in the media.
Revolution Medicines has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Insmed has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
94.3% of Revolution Medicines shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by company insiders. Comparatively, 3.0% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Revolution Medicines presently has a consensus price target of $74.64, indicating a potential upside of 60.63%. Insmed has a consensus price target of $149.06, indicating a potential downside of 5.61%. Given Revolution Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Revolution Medicines is more favorable than Insmed.
Summary
Revolution Medicines beats Insmed on 14 of the 17 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 10/6/2025 by MarketBeat.com Staff
